Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. IJ Pharmaceutical Research
  4. Articles

  5. Synthesis, Biological Evaluation, and Molecular Modeling Studies of New 8-methyl-4-oxo-1,4-dihydroquinoline-3-carbohydrazides as Potential Anti-HIV Agents
  6. Scopus by Title (Ref)

IJ Pharmaceutical Research

Home
Current IssueAll IssuesIn PressAccepted Manuscripts
SearchInstructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Spectrum of anti-inflammatory, anti-infectious and anti-tumor activity of quinazoline and quinazolinone derivatives (review)

- Manvelyan M.M. , et al.

2. Design, synthesis, molecular dynamics studies and biological evaluations of 4-hydroxy-5-pyrrolinone-3-carbohydrazides as HIV-1 integrase inhibitors

- Karimi N. , et al.

3. Green synthesis and anti-tumor efficacy via inducing pyroptosis of novel 1H-benzo[e]indole-2(3H)-one spirocyclic derivatives

- Wu J. , et al.

4. Efficient Synthesis of Acyclic Nucleosides by N-Alkylation Using K2CO3 Supported with Natural Phosphate (K2CO3@NP) as Catalyst and Docking Study Against VIH

- Ouzebla D. , et al.

HomeSearchInstructionsAPC

Archives

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.